MOTIVATION: Novel approaches are needed for discovery of targeted therapies for non-small-cell lung cancer (NSCLC) that are specific to certain patients. Whole genome RNAi screening of lung cancer cell lines provides an ideal source for determining candidate drug targets. RESULTS: Unsupervised learning algorithms uncovered patterns of differential vulnerability across lung cancer cell lines to loss of functionally related genes. Such genetic vulnerabilities represent candidate targets for therapy and are found to be involved in splicing, translation and protein folding. In particular, many NSCLC cell lines were especially sensitive to the loss of components of the LSm2-8 protein complex or the CCT/TRiC chaperonin. Different vulnerabilities ...
Non-small cell lung cancer (NSCLC) is one of the most common cancers globally and has a 5-year survi...
Non-Small Cell Lung Cancer (NSCLC) represents ∼85% of all lung cancers and ∼15-20% of them are chara...
IntroductionWith a 5-year survival rate of only 16%, improvements in therapeutic strategies for the ...
SummaryContext-specific molecular vulnerabilities that arise during tumor evolution represent an att...
Thesis (Ph.D.)--University of Washington, 2020Small Cell Lung Cancer (SCLC) is a highly aggressive a...
Background: Treatment of NSCLC has been revolutionized in recent years with the introduction of seve...
Background: Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC account...
There is high expectation for significant improvements in cancer patient care after completion of th...
The advent of molecular targeted agents is changing the treatment of solid tumors. In non-small-cell...
The aim of this thesis is to improve diagnostic methods to identify genomic aberrations with clinica...
Lung cancer is the commonest cause of cancer death in the world and carries a poor prognosis for mos...
The identification of genes responsible for causing cancers from gene expression data has had varied...
There is high expectation for significant improvements in cancer patient care after completion of th...
We present new modes of computational drug discovery in each of the three key themes of target ident...
Background: Lung cancer is the world's leading cause of cancer death, with a 5 year survival rate of...
Non-small cell lung cancer (NSCLC) is one of the most common cancers globally and has a 5-year survi...
Non-Small Cell Lung Cancer (NSCLC) represents ∼85% of all lung cancers and ∼15-20% of them are chara...
IntroductionWith a 5-year survival rate of only 16%, improvements in therapeutic strategies for the ...
SummaryContext-specific molecular vulnerabilities that arise during tumor evolution represent an att...
Thesis (Ph.D.)--University of Washington, 2020Small Cell Lung Cancer (SCLC) is a highly aggressive a...
Background: Treatment of NSCLC has been revolutionized in recent years with the introduction of seve...
Background: Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC account...
There is high expectation for significant improvements in cancer patient care after completion of th...
The advent of molecular targeted agents is changing the treatment of solid tumors. In non-small-cell...
The aim of this thesis is to improve diagnostic methods to identify genomic aberrations with clinica...
Lung cancer is the commonest cause of cancer death in the world and carries a poor prognosis for mos...
The identification of genes responsible for causing cancers from gene expression data has had varied...
There is high expectation for significant improvements in cancer patient care after completion of th...
We present new modes of computational drug discovery in each of the three key themes of target ident...
Background: Lung cancer is the world's leading cause of cancer death, with a 5 year survival rate of...
Non-small cell lung cancer (NSCLC) is one of the most common cancers globally and has a 5-year survi...
Non-Small Cell Lung Cancer (NSCLC) represents ∼85% of all lung cancers and ∼15-20% of them are chara...
IntroductionWith a 5-year survival rate of only 16%, improvements in therapeutic strategies for the ...